New JITC Articles Now Available! |
||||||||||||
|
||||||||||||
Letter from the EditorDear Colleagues, As the Editor-in-Chief of the Journal for ImmunoTherapy of Cancer (JITC), the official journal of the Society for Immunotherapy of Cancer (SITC), I am delighted to share with you the progress and new developments within the Journal. This is a very exciting time for the field of cancer immunotherapy, and JITC is making great strides to become the leading peer-reviewed, open-access journal of its kind in the field. Submissions to and published articles in the Journal have almost doubled since this time last year. More leaders in the field are citing noteworthy JITC articles in their own research and many are choosing to publish this research in JITC. Due to the tremendous growth of the Journal, we are pleased to announce that JITC will soon encompass more of the cutting-edge, impactful articles that leaders in the field are reading and citing every day. Stay tuned for more information on the newest addition to the Journal: the Commentary/Editorials section led by Dr. Christian Capitini of the University of Wisconsin - Madison. Dr. Capitini is an esteemed colleague in the field concentrating on Pediatric Oncology. We are extremely excited to add him to the JITC family and expand the Journal with this new section. The increasing number of submissions calls for additional support, so to help manage the profusion of manuscripts to JITC, the Journal will also be hiring a Managing Editor to assist the Editorial Board and help solicit insightful articles from more luminaries in the field. If you or someone you know is interested in joining the JITC team as our Managing Editor, please inquire at jitceditor@sitcancer.org. On behalf of the Editorial Board, thank you for all you have done to help JITC as it continues on its journey to become one of the preeminent journals in the field. We have much work ahead of us, but with your help, the Journal will continue to grow and prosper. Stay tuned for more exciting announcements to come from the Journal and the Society. Sincerely, Pedro J. Romero, MD Research Articles
From the Authors “The report describes a case with an acute autoimmune myocarditis due to immune stimulation after treatment with pembrolizumab for metastatic uveal melanoma,” said Dr. Heinz Läubli. “This first documentation of a potentially life-threatening complication of anti-PD-1 treatment is important to all oncologists treating patients with these emerging immuno-modulatory agents.”
From the Authors "Cancer immunotherapy has conventionally relied on cell-mediated immunity, while successful infectious disease vaccines have been shown to induce humoral immunity,” said Dr. Elias Sayour. “RNA based cancer vaccines are especially suited to bridge these modalities. Here we review common infectious disease vaccines and the progress in RNA cancer vaccine development including novel encapsulating strategies and safe targeting mechanisms."
From the Authors "Our humanized mouse model offers a flexible platform for reconstituting the dynamic interaction that occurs between a growing human tumor and the human immune system, hopefully providing further insight into the biology of TIL and an opportunity to test various immunotherapeutic strategies for their impact on cancer biology and growth,” said Dr. Airi Harui.
From the Authors “AGS-003 (autologous dendritic cells loaded with patient’s own tumor mRNA) may provide a useful platform for delivery of immunotherapy safely and, in combination with Sunitinib, elicited significant improvement in overall survival for patients with intermediate and poor risk metastatic renal cell carcinoma. This is currently being validated in a phase III (ADAPT) study,” said Dr. Asim Amin.
From the Authors “Following the singling out of Cancer Immunotherapy as the scientific breakthrough of the year 2013 by Science magazine, Nature published a string of five letters in its November 27 issue of 2014,” said Dr. Pedro Romero. “Here Emanuela Romano and myself summarize the reported findings and discuss them in light of the recent progress in the field of treatment of cancer based on blocking of the immune checkpoints CTLA-4 and PD-1/PD-L1.” March Highly Accessed Articles
2015 JITC Best Paper Awards: Submit Now!
|
||||||||||||
.jpg)
.png)
Submit your Research to JITC!
SITC Members and non-members alike are invited to submit manuscripts to the Society's official journal.
Categories
- Basic Tumor Immunology
- Case Reports
- Clinical/Translational Cancer Immunotherapy
- Commentary/Editorials - Coming Soon!
- Immunotherapy Biomarkers
- Reviews
JITC Editor-in-Chief
Pedro J. Romero, MD - University of Lausanne
Section Editors
Lisa H. Butterfield, PhD - University of Pittsburgh Cancer Institute
Christian Capitini, MD - University of Wisconsin - Madison
Bernard A. Fox, PhD - Earle A. Chiles Research Institute, Providence Cancer Center
Thomas F. Gajewski, MD, PhD - University of Chicago
F. Stephen Hodi, Jr., MD - Dana-Farber Cancer Institute
Cornelis J.M. Melief, MD, PhD - ISA Therapeutics BV
Walter J. Urba, MD, PhD - Earle A. Chiles Research Institute, Providence Cancer Center
To view the full editorial board, please visit: www.immunotherapyofcancer.org/about/edboard.
Waived Article Processing Charges for SITC Members Extended into 2015!
As a thank you to our members, SITC is offering waived article processing charges extended throughout 2015 (a $2,500 USD savings). For your membership code, please contact the SITC office at +1(414) 271-2456.
Visit SITC Online |
||||
| www.sitcancer.org | About SITC | Meetings | Membership | Support SITC |
